Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will ...

Cleaning his plate — and sometimes a second plate — was a household requirement during Charles’s childhood. “It served me ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...